We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+30.93%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$169M
AUM Growth
+$14.2M
Cap. Flow
-$13.9M
Cap. Flow %
-8.24%
Top 10 Hldgs %
94.71%
Holding
21
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$12.1M
2
APTX
Aptinyx Inc. Common Stock
APTX
+$1.84M
3
ITRM
Iterum Therapeutics
ITRM
+$9

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
1
Arvinas
ARVN
$572M
$57.4M 34.04%
1,289,521
– –
RLYB icon
2
Rallybio
RLYB
$85.8M
$33.3M 19.76%
287,700
– –
DCPH
3
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$22.4M 13.28%
1,209,571
– –
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.68B
$15.3M 9.07%
1,553,661
– –
DICE
5
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$11.3M 6.7%
556,693
– –
COGT icon
6
Cogent Biosciences
COGT
$7.24B
$7.48M 4.44%
501,530
– –
ALEC icon
7
Alector
ALEC
$198M
$3.21M 1.91%
339,569
– –
PASG icon
8
Passage Bio
PASG
$14.1M
$3.12M 1.85%
124,896
– –
AMYT
9
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$3.11M 1.85%
449,737
– –
HARP
10
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$3.06M 1.82%
315,670
– –
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.92B
$2.77M 1.64%
141,000
– –
CMRX
12
DELISTED
Chimerix, Inc.
CMRX
$2.36M 1.4%
1,224,600
– –
RCOR
13
DELISTED
Renovacor, Inc.
RCOR
$1.69M 1%
670,689
– –
ARAV
14
DELISTED
Aravive, Inc. Common Stock
ARAV
$773K 0.46%
946,423
– –
XFOR icon
15
X4 Pharmaceuticals
XFOR
$438M
$573K 0.34%
11,167
– –
PDSB icon
16
PDS Biotechnology
PDSB
$43.4M
$348K 0.21%
117,242
– –
TECX
17
Tectonic Therapeutic
TECX
$585M
$203K 0.12%
26,296
– –
ITRM
18
DELISTED
Iterum Therapeutics
ITRM
$157K 0.09%
97,084
-3
-0% -$9
ADXN
19
Addex Therapeutics
ADXN
$7.34M
$40K 0.02%
2,500
– –
APTX
20
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-3,290,079
Closed -$1.84M
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-219,251
Closed -$12.1M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q3 2022 Portfolio in Review

As of Q3 2022, New Leaf Venture Partners held 21 positions worth $169M, up 9.2% from $154M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

New Leaf Venture Partners withdrew a net $13.9M in Q3 2022, closing 2 positions and reducing 1 holding. Its most notable exit was Sierra Oncology, Inc. Common Stock, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • New Leaf Venture Partners's biggest Q3 2022 reduction was Iterum Therapeutics, cutting an estimated $9.
  • New Leaf Venture Partners fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $12.1M.
  • New Leaf Venture Partners's ten largest holdings make up 95% of its $169M portfolio in Q3 2022.
  • New Leaf Venture Partners opened 0 new positions and closed 2 in Q3 2022.
  • New Leaf Venture Partners's portfolio value rose 9.2% quarter-over-quarter to $169M.

Based on New Leaf Venture Partners's 13F filing for Q3 2022, filed 10 Nov 2022.